Page 1,589«..1020..1,5881,5891,5901,591..1,6001,610..»

Are baby, wisdom teeth the next wave in stem cell treatment? – CNN

Posted: April 26, 2017 at 3:41 pm

It's based on experimental research that suggests stem cells extracted from the pulp of these teeth might someday regrow a lost adult tooth or offer other regenerative medicine benefits -- some potentially life-saving.

"So I'll try not to get emotional here, but my husband was diagnosed with acute myeloid leukemia in 2011," said Bassetto, of Naperville, Illinois, head of a sales team at a software company.

In 2012, her husband, James, had a stem cell transplant to restore his bone marrow and renew his blood.

"He was very fortunate. He was one of six kids, and his brother was a perfect match," she said. She noted that her two children, Madeline, 23, and Alex, 19, may not be so lucky if they develop health problems, since they have only each other; the chance of two siblings being a perfect stem cell match is only 25%.

Unfortunately, her husband's stem cell transplant was not successful. He developed graft-versus-host disease, where his brother's donated stem cells attacked his own cells, and he died shortly afterward.

However, she says, the transplant had given him a chance at a longer life.

Last year, when her son saw a dentist for wisdom tooth pain, a brochure for dental stem cell storage caught Bassetto's eye and struck a chord.

"I know stem cells have tremendous health benefits in fighting disease, and there's a lot ways they're used today," she said. "Had my husband had his own cells, potentially, his treatment could have been more successful."

Medical breakthroughs happen all the time, said Bassetto. "Who knows what potential there is 20 years, 40 years down the road, when my son is an adult or an aging adult?

"Almost like a life insurance policy, is how I viewed it," she said.

Some scientists see storing teeth as a worthwhile investment, but others say it's a dead end.

"Research is still mostly in the experimental (preclinical) phase," said Ben Scheven, senior lecturer in oral cell biology in the school of dentistry at the University of Birmingham. Still, he said, "dental stem cells may provide an advantageous cell therapy for repair and regeneration of tissues," someday becoming the basis for reconstructing bone tissue, retinas and even optic neurons.

Dr. Pamela Robey, chief of the craniofacial and skeletal diseases branch of the National Institute of Dental and Craniofacial Research, acknowledges the "promising" studies, but she has a different take on the importance of the cells.

"There are studies with dental pulp cells being used to treat neurological disorders and problems in the eye and other things," Robey said. The research is based on the idea that these cells "secrete factors that encourage local cells to begin the repair process."

"The problem is, these studies have really not been that rigorous," she said, adding that many have been done only in animals and so provide "slim" evidence of benefits. "The science needs a lot more work."

Robey would know. Her laboratory discovered dental stem cells in 2003.

"My fellows, Songtao Shi and Stan Gronthos, did the work in my lab," Robey said. "Songtao Shi is a dentist, and basically he observed that, when you get a cavity, you get what's called 'reparative dentin.' In other words, the tooth is trying to protect itself from that cavity, so it makes a little bit of dentin to kind of plug the hole, so to speak."

Dentin is the innermost hard layer of tooth that lies beneath the enamel. Underneath the dentin is a soft tissue known as pulp, which contains the nerve tissue and blood supply.

Observing dentin perform reparative work, Shi hypothesized that this must mean there's a stem cell within the tooth that's able to activate and make dentin. So if you wanted to grow an adult tooth instead of getting an implant, knowing how to make dentin would be the start of the process, explained Robey.

Pursuing this idea, Shi, Gronthos and the team conducted their first study with wisdom teeth. They discovered that pulp cells in these third molars did indeed make dentin, but the cells found in baby teeth, called SHED (stem cells from human exfoliated deciduous teeth), had slightly different properties.

"The SHED cells seem to make not only dentin but also something that is similar to bone," Robey said. This "dentin osteogenic material" is a little like bone and a little like dentin -- "unusual stuff," she said.

There is a meticulous process for extracting stem cells from the pulp.

"We very carefully remove any soft tissue that's adhering to the tooth. We treat it with disinfectant, because the mouth is not really that clean," Robey said, laughing.

Scientists then use a dental drill to pass the enamel and dentin -- "kind of like opening up a clam," said Robey -- to get to the pulp. "We take the pulp out, and we digest it with an enzyme to release the cells from the matrix of the pulp, and then we put the cells into culture and grow them."

According to Laning, even very small amounts of dental pulp are capable of producing many hundreds of millions of structural stem cells.

Harvesting dental stem cells is not a matter of waiting for the tooth to fall out and then quickly calling your dentist. When a baby tooth falls out, the viability of the pulp is limited if it's not preserved in the proper solution.

American Academy of Pediatric Dentistry President Dr. Jade Miller explained that "it's critical that the nerve tissue in that pulp tissue, the nerve supply and blood supply, still remain intact and alive." Typically, the best baby teeth to harvest are the upper front six or lower front six -- incisors and cuspids, he said.

For a child between 5 and 8 years of age, it's best to extract the tooth when there's about one-third of the root remaining, Miller said: "It really requires some planning, and so parents need to make this decision early on and be prepared and speak with their pediatric dentist about that."

Bassetto found the process easy. All it involved was a phone call to the company recommended by her dentist.

"They offer a service where they grow the cells and save those and also keep the pulp of the tooth without growing cells from it," she said. "I opted for both." From there, she said, the dentist shipped the extracted teeth overnight in a special package.

Bassetto said she paid less than $2,000 upfront, and now $10 a month for continued storage.

So is banking teeth something parents should be doing?

In a policy statement, the American Academy of Pediatric Dentistry "encourages dentists to follow future evidence-based literature in order to educate parents about the collection, storage, viability, and use of dental stem cells with respect to autologous regenerative therapies."

"Right now, I don't think it is a logical thing to do. That's my personal opinion," said Robey of the National Institute of Dental and Craniofacial Research. As of today, "we don't have methods for creating a viable tooth. I think they're coming down the pike, but it's not around the corner."

Science also does not yet support using dental pulp stem cells for other purposes.

"That's not to say that in the future, somebody could come up with a method that would make them very beneficial," Robey said.

Still, she observed, if science made it possible to grow natural teeth from stem cells and you were in a car accident, for example, and lost your two front teeth, you'd probably be "very happy to give up a third molar to use the cells in the molar to create new teeth." Third molars are fairly expendable, she said.

Plus, Robey explained, it may not be necessary to bank teeth: Another type of stem cell, known as induced pluripotent stem cells, can be programmed into almost any cell type.

"It's quite a different story than banking umbilical cord blood, which we do know contains stem cells that re-create blood," Robey said.

"So cord blood banking -- and now we have a national cord blood bank as opposed to private clinics -- so there's a real rationale for banking cord blood, whereas the rationale for banking baby teeth is far less clear," Robey said.

And there's no guarantee that your long-cryopreserved teeth or cells will be viable in the future. Banking teeth requires proper care and oversight on the part of cryopreservation companies, she said. "I think that that's a big question mark. If you wanted to get your baby teeth back, how would they handle that? How would they take the tooth out of storage and isolate viable cells?"

Provia's Laning, who has "successfully thawed cells that have been frozen for more than 30 years," dismissed such ideas.

"Cryopreservation technology is not the problem here," he said. "Stem cells from bone marrow and other sources have been frozen for future clinical use in transplants for more than 50 years. Similarly, cord blood has a track record of almost 40 years." The technology for long-term cryopreservation has been refined over the years without any substantial changes, he said.

Despite issues and doubts, Miller, of the pediatric dentistry academy, said parents still need to consider banking baby teeth.

A grandparent, he is making the decision for his own family.

"It's really at its infancy, much of this research," he said. "There's a very strong chance there's going to be utilization for these stem cells, and they could be life-saving."

He believes that saving baby teeth could benefit not only his grandchildren but also their older siblings and various other family members if their health goes awry and a stem cell treatment is needed.

"The science is strong enough to show it's not science fiction," Miller said. "There's going to be a significant application, and I want to give my grandkids the opportunity to have those options."

Aside from cost, Miller said there are other considerations: "Is this company going to be around in 30, 40 years?" he asked. "That's not an easy thing to figure out."

Having taken the leap, Bassetto doesn't worry.

"In terms of viability, you know, if something were to happen with the company, you could always get what's stored and move it elsewhere, so I felt I was protected that way," she said. She feels "pretty confident" with her decision and plans to store her grandchildren's baby teeth.

Still, she concedes that her circumstances may be rare.

"Not everybody's going to be touched by some kind of disease where it just hits home," Bassetto said. "For me, that made it a no-brainer."

See the rest here:
Are baby, wisdom teeth the next wave in stem cell treatment? - CNN

Posted in Cell Therapy | Comments Off on Are baby, wisdom teeth the next wave in stem cell treatment? – CNN

Cellectis to Present at the American Society of Gene & Cell Therapy … – Yahoo Finance

Posted: April 26, 2017 at 3:41 pm

NEW YORK--(BUSINESS WIRE)--

Regulatory News:

Cellectis (ALCLS.PA) (CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that data on its gene-edited allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.

Oral presentation:

Development of Gene Edited Allogeneic CAR T-Cell Therapy Philippe Duchateau, PhD. Chief Executive Officer, Cellectis

Session: 300 - Clinical Advancement of Gene Editing-Moving New Science to the Clinic - Organized by the Clinical Trials and Regulatory Affairs Committee

Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST Lincoln 2, 3, 4

Poster presentations:

176 - Genome-Wide Analysis of TALEN Activity in Primary Cells Brian Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent Poirot

Session: Gene Targeting and Gene Correction I Wednesday May 10, 2017 at 5:30 PM EST Exhibit Hall A & B South

114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting CD22 with CAR T-cells Anne-Sophie Gautron, Ccile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes Gouble, Laurent Poirot, Julianne Smith

Session: Cancer-Immunotherapy, Cancer Vaccines I Wednesday May 10, 2017 from 5:30 PM to 7:30pm EST Exhibit Hall A & B South

372 - Manufacturing of Gene-Modified Mouse CAR T-Cells Laurent Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau

Session: Gene Targeting and Gene Correction II Thursday May 11, 2017 from 5:15 PM to 7:15 PM EST Exhibit Hall A & B South

About Cellectis

Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The companys mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN products and meganucleases as well as its pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis goal is to create innovative products in multiple fields and with various target markets.

Cellectis is listed on the Nasdaq market (CLLS) and on the NYSE Alternext market (ALCLS.PA). To find out more about us, visit our website: http://www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark owned by the Cellectis Group

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Companys objectives based on the current expectations and assumptions of the Companys management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170425006830/en/

More here:
Cellectis to Present at the American Society of Gene & Cell Therapy ... - Yahoo Finance

Posted in Cell Therapy | Comments Off on Cellectis to Present at the American Society of Gene & Cell Therapy … – Yahoo Finance

SAVSU and TrakCel announce collaboration to integrate Cell … – PR Newswire (press release)

Posted: April 26, 2017 at 3:41 pm

TrakCel's Cellular Orchestration platform facilitates efficiency and compliance to quality standards in cell therapy manufacturing by enabling program-critical information to be collated, tracked and and documented. Detailed processes and managed workflows for every participant in the value chain enable safe and efficient scaling outward and upward as production increases. Conditional logic workflows for all participants including clinicians, logistics and manufacturing partners ensure standardization andcompliance with validated procedures.

Bruce McCormick, President of SAVSU Technologies, remarked, "Our optimized technologies represent the next generation of integrated, cloud-connected cold chain technologies. We are very pleased to collaborate with TrakCel and look forward to integrating our respective data platforms to provide even more value to our mutual customers. We are committed to driving a paradigm shift away from traditional, risk-laden cold chain practices based on the use of poor performing shipping containers and disconnected data systems."

Ravi Nalliah, CEO at TrakCel, commented, "We scoped the packaging and cold chain technologies space to identify best of breed ecosystem partners. SAVSU is so far ahead of traditional container and data logger suppliers, and we are very keen to integrate their innovations into our Cell Orchestration Platform. The timing of this collaboration is perfect as the cell therapy market continues to mature and awareness is peaked on the need to use better tools to enable clinical trial success, commercial scale-out, and reimbursement supported by evidence of compliance throughout manufacturing, distribution and patient administration."

Chain Link Research and Pharmaceutical Commerce market research estimate that there are 80 million to 130 million annual temperature sensitive pharmaceutical shipments requiring cold chain management, resulting in $12 billion spent annually on cold chain logistics, with $9 billion for transportation and $3 billion for specialized tertiary packaging and instrumentation such as insulated boxes, blankets, phase change materials, temperature sensors and data loggers. The use of currently available cold technologies results in $15 billion to $35 billion spent annually replacing products lost due to temperature excursions.

About SAVSU Technologies SAVSU is a leading designer and manufacturer of innovative, high performance, cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials.

For more information please visit http://www.savsu.com.

About TrakCel TrakCel's cell, gene and immunotherapy management solution improves clinical study efficacy and accelerates global scale-up and scale-out by implementing communications technology to integrate the delivery path from needle-to-needle. The technology provides interactive instructions to professionals across the supply chain and gives stakeholders on-demand visibility of procedural results and chain-of-custody data for immediate traceability, validation and compliance audits.

TrakCel technology is increasingly being adopted by leaders in the cell, gene and immunotherapy industry. TrakCel is headquartered in Cardiff, Wales with a U.S. offices in Newport Beach, California and Bridgewater, NJ.

For more information please visitwww.trakcel.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/savsu-and-trakcel-announce-collaboration-to-integrate-cell-therapy-manufacturing-and-cold--chain-data-management-platforms-300444497.html

SOURCE SAVSU Technologies

http://www.savsu.com

See the original post:
SAVSU and TrakCel announce collaboration to integrate Cell ... - PR Newswire (press release)

Posted in Cell Therapy | Comments Off on SAVSU and TrakCel announce collaboration to integrate Cell … – PR Newswire (press release)

Regenerative cell therapy, tissue engineering are future treatments – ModernMedicine

Posted: April 26, 2017 at 3:41 pm

Regenerative cell therapy, tissue engineering are future treatments
ModernMedicine
There have been major changes in the way keratoplasty has been performed over the past 15 years. Data from the Singapore Corneal Transplant Study shows there have been improved outcomes in the lamellar surgical techniques compared to the full ...

Read the rest here:
Regenerative cell therapy, tissue engineering are future treatments - ModernMedicine

Posted in Cell Therapy | Comments Off on Regenerative cell therapy, tissue engineering are future treatments – ModernMedicine

TxCell to Provide CAR-Treg Update in Upcoming Cell Therapy Conferences – Business Wire (press release)

Posted: April 26, 2017 at 3:41 pm

VALBONNE, France--(BUSINESS WIRE)--Regulatory News:

TxCell SA (Paris:TXCL) (FR0010127662 TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, today announces that Stphane Boissel, CEO of TxCell, will present in upcoming cell therapy conferences.

Mr. Boissel will present an update on TxCells ENTrIA CAR-Treg platform at the 5th Alliance for Regenerative Medicine (ARM) Annual Cell & Gene Therapy Investor Day which will be held on April 27, 2017 in Boston (US). The TxCell presentation will be coupled with an interview by Joshua Schimmer, MD, Managing Director and Senior Biotech Equity Research Analyst at Piper Jaffray & Co. The presentation and interview will take place at 5:00pm local time (Harborside Room).

Mr. Boissel will also be participating to a panel discussion entitled Biotech Perspective: The opportunities of cell & gene therapy and why now? at the Investment for Advanced Therapies Summit which will be held on May 3, 2017 in London (UK). This panel discussion will take place at 9:15am local time.

In addition, Mr. Boissel and other members from TxCell will attend the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting which will be held on May 3-6, 2017, in London.

About TxCell http://www.txcell.com

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohns disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplant rejection.

TxCell is the only clinical-stage cellular therapy company fully dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing antigen-specific Tregs. This antigen specificity may either come from genetic modifications with Chimeric Antigen Receptor (CAR) or from pre-existing Treg cell T-Cell Receptor (TCR). TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs.

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 46 employees.

Next events

Financial and business conferences

5th Annual Cell & Gene Therapy Investor Day (ARM)

Scientific and medical conferences

22e congrs Nantes Actualits Transplantation (NAT)

Forward-Looking Statements - TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCells ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Companys products, which may not succeed, or in the delivery of TxCells products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 Risk factors of the 2015 document de rfrence (registration document) approved by the AMF on May 24, 2016 under number R.16-048 and in the section 5.1 of the update of the registration document filed with the AMF on January 24, 2107 under number D.16-0346-A01. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be accurate, precise and fairly presented), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Read more here:
TxCell to Provide CAR-Treg Update in Upcoming Cell Therapy Conferences - Business Wire (press release)

Posted in Cell Therapy | Comments Off on TxCell to Provide CAR-Treg Update in Upcoming Cell Therapy Conferences – Business Wire (press release)

Global Stem Cell Therapy Market – Analysis, Technologies and Forecasts to 2021 – Increasing Demand to Develop … – PR Newswire (press release)

Posted: April 26, 2017 at 3:41 pm

The global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

The report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is evolution of new destinations in the development of stem cell therapies. Traditionally, the US and European countries are the key destinations for clinical trials for stem cell therapy products. However, the transformation of regulatory landscape in countries such as Japan and South Korea has made these regions as attractive destinations for the development of stem cell therapy products.

According to the report, one of the major drivers for this market is increase in federal funding in stem cell therapy. Research and clinical trials of stem cell therapy require huge investment, which many research institutes and small companies cannot afford. Therefore, many federal organizations provide funding to these institutes and small companies to help their innovative ideas in the development of stem cell therapies. Worldwide, many government organizations have noticed the importance of regenerative medicine, and thus they have allocated funds and grants in that area. For instance, in the US, the NIH and CIRM provide most of the funds.

Key vendors

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Understanding of stem cell therapy

Part 06: Ethical issues and regulatory landscape

Part 07: Key clinical trials

Part 08: Market landscape

Part 09: Market segmentation by therapy

Part 10: Market segmentation by applications

Part 11: Geographical segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

Part 18: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/gdv8s6/global_stem_cell

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-stem-cell-therapy-market---analysis-technologies-and-forecasts-to-2021---increasing-demand-to-develop-effective-drugs-for-cardiology-and-degenerative-disorders---research-and-markets-300444066.html

SOURCE Research and Markets

http://www.researchandmarkets.com

Here is the original post:
Global Stem Cell Therapy Market - Analysis, Technologies and Forecasts to 2021 - Increasing Demand to Develop ... - PR Newswire (press release)

Posted in Cell Therapy | Comments Off on Global Stem Cell Therapy Market – Analysis, Technologies and Forecasts to 2021 – Increasing Demand to Develop … – PR Newswire (press release)

Lilly Assures Market As Diabetes Stumbles – Seeking Alpha

Posted: April 26, 2017 at 3:41 pm

As the diabetes wars have raged, Eli Lilly's (NYSE:LLY) balanced portfolio has helped insulate it from the share price losses dealt to competitor Novo Nordisk (OTCPK:NONOF). But even Lilly can have an off quarter.

Trulicity's growth was more than offset by below-consensus sales for Basaglar and Jardiance - the underperformance of the last of these was surprising given that it has begun marketing on its cardiovascular benefit. When combined with last week's US rejection of rheumatoid arthritis entry Olumiant, these disappointments forced Lilly executives to reassure investors that the company's medium-term guidance of 5% growth could still be met.

Lilly shares fell 3% today following the release of first-quarter results, removing $2.7bn in market valuation. Since the Olumiant complete response letter was announced, shares have fallen 6% (Olumiant setback opens the door to rivals, April 18, 2017).

Bernstein analyst Tim Anderson chalked up some of the losses to profit-taking - before the Olumiant news, shares were up 16% on the year - but acknowledged the effect of Olumiant and diabetes revenue on investor sentiment.

Topline good

In the long view, the Indiana-based group had a positive quarter, with revenue of $5.2bn and earnings per share of $0.98 in line with investor expectations. However, having just got over the news of Olumiant - rejected because of questions over the most efficacious dose and safety characterization - news that diabetes was not necessarily firing on all cylinders was not taken well.

Expectations for Jardiance remain high since it is the first of the SGLT2 class to be allowed to market on the basis of averting cardiovascular death in diabetics, although it could very well be chased by competitors Invokana, from Johnson & Johnson, and Farxiga, from Astrazeneca (NYSE:AZN) (ACC - Jardiance heart benefit looks like a class effect, March 20, 2017).

Lilly diabetes chief Enrique Conterno characterized the SGLT2 class as having flat growth before the cardiovascular data was included on the Jardiance label, but said that since marketing on that claim has begun new patient starts have risen 70% - the miss on Jardiance sales may simply reflect a mismatch between investor expectations and market realities.

Olumiant's bigger setback has investors questioning the 5% revenue growth forecast given that the drug is one of four new products that will post annual sales growth of $1bn or more to counteract losses due to patent expiries. Finance chief Derica Rice offered some comfort: "We've factored in that we won't have 100% success on every molecule" when preparing that forecast, he said.

Olumiant's failure to add US revenue does, however, increase the pressure on the rest of the portfolio to meet sales expectations. And Lilly's exposure to the volatile diabetes space raises the risk that that will not happen.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

See the rest here:
Lilly Assures Market As Diabetes Stumbles - Seeking Alpha

Posted in Diabetes | Comments Off on Lilly Assures Market As Diabetes Stumbles – Seeking Alpha

Decrease in cardiovascular diseases benefits persons with diabetes … – Science Daily

Posted: April 26, 2017 at 3:41 pm

The incidence of cardiovascular diseases in Sweden has decreased sharply since the late 1990s. These are the findings of a study from Sahlgrenska Academy which included almost three million adult Swedes. In relative terms, the biggest winners are persons with type 1 and type 2 diabetes.

"This is a huge improvement and a testament to the improvements in diabetes and cardiovascular care throughout Sweden," says Aidin Rawshani, medical doctor and doctoral student in molecular and clinical medicine.

The study, which was published in The New England Journal of Medicine, shows that the incidence of cardiovascular diseases and deaths among individuals with diabetes in Sweden dropped significantly between 1998 and 2014. The population in general exhibited the same trend, albeit to a smaller extent.

Among persons with type 1 diabetes, with an average age of 35 years, the incidence pf cardiovascular disease was reduced by 40 per cent during the period in question. In the control group of persons of similar age but without diabetes, the decrease was 10 per cent.

Among individuals with type 2 diabetes, with an average age of 65 years, the incidence of cardiovascular disease decreased by 50 per cent. Among control persons of similar age without diabetes, the decrease was 30 per cent.

Surprising results

"We were surprised by the results, specially for persons with diabetes. Some smaller studies in the past have indicated that numbers were improving, but nothing of this magnitude," says Aidin Rawshani.

In total, approximately 2.96 million individuals were studied, of which 37,000 had type 1 diabetes and 460,000 had type 2 diabetes. The results of the study are based on linked processing of data from the National Diabetes Register, the Cause of Death Register and the part of the Patient register that concerns inpatient care.

In addition to matching by age and gender, the groups that were compared were also matched geographically using register data from LISA (the longitudinal integration database for health insurance and labour market studies).

The deaths that took place in the groups during the study period were almost exclusively related to cardiovascular disease. Individuals with diabetes have previously shown to suffer a risk of cardiovascular disease and early death that was between two and five times as high as in the general population.

Better risk control

"One of the main findings of the study is that both deaths and the incidence of cardiovascular disease is decreasing in the population, both in matching control groups and among persons with type 1 and type 2 diabetes. One paradoxical finding is that individuals with type 2 diabetes have seen a smaller improvement over time regarding deaths compared to the controls, while persons with type 1 diabetes have made an equal improvement to the controls," notes Aidin Rawshani.

The positive trends that have been observed in the study are most likely due to an increased use of preventative cardiovascular medicines, advances in the revascularisation of atherosclerotic disease and improved use of instruments for continual blood sugar monitoring, and the fact that Swedish diabetes care has generally worked well with good treatment guidelines and quality assurance efforts.

"Out study and analysis does not include explanations of these trends, but we believe that it is a matter of better control of risk factors, better education patients, better integrated treatment systems for individuals with chronic illnesses and individual care for persons with diabetes. There is often an entire team working with a patient, ensuring that their needs are met," says Aidin Rawshani.

Story Source:

Materials provided by University of Gothenburg. Note: Content may be edited for style and length.

See the article here:
Decrease in cardiovascular diseases benefits persons with diabetes ... - Science Daily

Posted in Diabetes | Comments Off on Decrease in cardiovascular diseases benefits persons with diabetes … – Science Daily

800-Mile Ride Through ‘Diabetes Belt’ Takes Cyclist From Chicago To Atlanta – DNAinfo

Posted: April 26, 2017 at 3:41 pm

CHICAGO Edwin Velarde is tackling his Type 1 diabetes with what he's calling an "epic" bike challenge that begins in Chicago next month.

Velarde, a former Chicago resident who now lives in Oak Park, Calif., will pedal his bike from the Adler Planetarium to Atlanta a journey of about 800 miles from May 30-June 8. He's raising money for the American Diabetes Association.

"I will do all I can during this ride to promote healthy lifestyles and inspire others to take control of their wellness," said Velarde.

He said he's excited to meet "people along the way and able to talk about diabetes, and how I manage my condition.

"Thats exciting as I hope there are possibilities of inspiring others," he said. "I change one life, it makes it worth the effort through all this."

Edwin Velarde

Velarde was diagnosed with diabetes when he was 29. He said he struggled with high blood glucose until a friend gave him a bike a few years ago. Since then, he's avoided thousands of insulin injections and kept his blood glucose levels stable.

His route will take him through Terre Haute, Ind., Evansville, Ind., Nashville and Chattanooga, Tenn. before arriving in Atlanta. He also posted information about his ride to The Chainlink site hoping for guidance on the safest routes from Chicago.

The Centers for Disease Control and Prevention considers the area the "Diabetes Belt" of America because 11.7 percent of the people within it have diagnosed diabetes, compared to 8.5 percent outside the belt.

Velarde will arrive in Chicago a few days early to train on the Lakefront Trail and near his former home in North Park.

"I am doing this ride to give back by raising awareness about diabetes and modest funds for the American Diabetes Association," he said. "I am hoping to meet other cyclists around the places I pass through. Theres this bond I think among cyclists and would like to expand my circle. Maybe they can spread the word also about what Im trying to do, maybe even ride with me parts of my epic journey."

For more information on Velarde's challenge, click here.

See the original post:
800-Mile Ride Through 'Diabetes Belt' Takes Cyclist From Chicago To Atlanta - DNAinfo

Posted in Diabetes | Comments Off on 800-Mile Ride Through ‘Diabetes Belt’ Takes Cyclist From Chicago To Atlanta – DNAinfo

The Kid’s Doctor: Why is childhood diabetes on the rise? – Chicago Sun-Times

Posted: April 26, 2017 at 3:41 pm

Diabetes continues to be a growing problem among our nations children. Did you know that every year there are more than 25,000 children diagnosed with diabetes?

To begin with there are two different types of childhood diabetes, type 1 and type 2; and while both cause an elevated blood sugar, they also differ in many ways.

Type 1 diabetes was formerly called juvenile onset diabetes and is typically diagnosed in children and adolescents. Only 5 percent of those with diabetes have type 1. Many parents worry that their child may develop diabetes because they eat too much sugar. While eating sugar is not good for you, it does not directly cause type 1 diabetes.

Type 1 diabetes is an autoimmune disease in which the immune system attacks and destroys the beta cells (insulin producing cells) of the pancreas. Scientists are not exactly sure why this occurs, but it seems to be a combination of genetic and environmental factors, and actually has nothing to do with diet.

Type 1 diabetes comes on suddenly and causes dependence on insulin for the rest of the childs life. The symptoms of type 1 diabetes usually include extreme thirst, frequent urination (day and night), increased appetite and sudden weight loss. Children who develop type 1 diabetes appear tired, thin and sick. To many parents who worry that their child is diabetic, I tell them that they really cannot miss the symptoms and that just drinking a lot of water will not be the only symptom.

Fortunately, the ways in which insulin is given continues to improve and most children now use an insulin pump, which delivers insulin in a more consistent manner than in previous years. But, even with new insulin delivery systems and the hopes for pancreas transplants, type 1diabetes is challenging for a family to manage.

Type 2 diabetes, which was previously called non-insulin dependent diabetes, differs in that it was previously typically diagnosed in adults, but it is now rising in children. In type 2 diabetes, the body isnt able to use insulin in the right way and the glucose in the blood stream is less able to enter the cells. This is called insulin resistance. So, the pancreas tries to produce even more insulin to keep blood sugar levels normal. Over many years the pancreas may wear out completely. Type 2 diabetes is sometimes controlled with an oral medication rather than insulin.

Type 2 diabetes seems to develop more frequently in those children who are overweight, less active and often have a parent with diabetes. As more children in this country have developed obesity, the number of cases of type 2 diabetes has also continued to rise. In many cases, if a child changes their lifestyle, eating a healthy diet, losing weight and exercising, the body may be able to restore normal insulin balance. In this way, type 2 diabetes differs from type 1 diabetes.

If you are concerned that your child is showing any signs of diabetes, make sure to consult your doctor. Continue to promote healthy eating habits and daily exercise.

Sue Hubbard, M.D. /The Kids Doctor; the kidsdr.com

Original post:
The Kid's Doctor: Why is childhood diabetes on the rise? - Chicago Sun-Times

Posted in Diabetes | Comments Off on The Kid’s Doctor: Why is childhood diabetes on the rise? – Chicago Sun-Times

Page 1,589«..1020..1,5881,5891,5901,591..1,6001,610..»